IRulya Therapeutics Inc. Common Stock
IRLA
81 hedge funds and large institutions have $715M invested in IRulya Therapeutics Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 10 reducing their positions, and 4 closing their positions.
450% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 4
320% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 10
37% more capital invested
Capital invested by funds: $523M → $715M (+$192M)
29% more funds holding
Funds holding: 63 → 81 (+18)
13.54% more ownership
Funds ownership: 38.95% → 52.49% (+14%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$85.3M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$36.5M |
| 3 |
BlackRock
New York
|
+$11.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.9M |
| 5 |
ECG
EPIQ Capital Group
San Francisco,
California
|
+$6.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.14M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$659K |
| 3 |
AA
ALPS Advisors
Denver,
Colorado
|
-$394K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$284K |
| 5 |
N
Natixis
Paris,
France
|
-$202K |
IRLA Hedge Fund Activity: Q2 2020 in Review
81 of the 4,889 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q2 2020, worth a combined $715M — up 37% from $523M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new IRLA positions and 4 closed out — a net gain of 18 holders — while 42 added to existing stakes and 10 trimmed.
The largest buyer was Capital World Investors, adding an estimated $85.3M. The largest seller was Ikarian Capital, exiting entirely with an estimated $1.14M sold.
- 81 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q2 2020, up from 63 in Q1 2020.
- Funds reported $715M of IRulya Therapeutics Inc. Common Stock stock for Q2 2020, up 37% quarter-over-quarter.
- 22 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q2 2020 and 4 closed out, a net change of +18 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q2 2020 was Capital World Investors, an estimated $85.3M added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q2 2020 was Ikarian Capital, an estimated $1.14M sold.
Based on aggregated 13F filings for Q2 2020.